RxDoctor Payments Data

Robert Cooper, MD

Geriatric Medicine · Baltimore, MDNPI 1235159898

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,774 of the $6,746 with a category attached, or 85.6%. It is spread thinly across 38 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Among geriatric medicine clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,746in general payments, 2019–2025

Across 310 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$814
  • Novo Nordisk$808
  • Lilly USA, LLC$729
  • AstraZeneca$676
  • Astellas Pharma US Inc$394
  • Pfizer$361
  • plus $3K from 32 others

What the payments were for

  • Speaking & faculty fees$391%
  • Travel & lodging$65810%
  • Food & beverage$5,77486%
  • Education$2754%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,746 in reported general payments places this provider in the 90th percentile of 112 geriatric medicine providers in Maryland.

See all geriatric medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$209,761
Medicare patients
362
Services billed
3,669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban137$122,452
FarxigaDapagliflozin Propanediol64$69,773
JardianceEmpagliflozin45$56,916
OzempicSemaglutide52$48,834
XareltoRivaroxaban29$37,837
JanuviaSitagliptin Phosphate21$33,074
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$18,417
MyrbetriqMirabegron24$16,314
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog67$14,534
MounjaroTirzepatide13$12,085
Breo ElliptaFluticasone/Vilanterol26$11,376
LinzessLinaclotide13$10,599
Atorvastatin Calcium591$7,331
Novolog FlexpenInsulin Aspart14$5,141
Losartan Potassium352$4,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$361$125,311148 claims
AstraZenecaFarxiga$676$69,77364 claims
Boehringer IngelheimJardiance$357$56,91645 claims
Novo NordiskOzempic$808$48,83452 claims
Johnson & JohnsonXarelto$15$37,83729 claims
MerckJanuvia$309$33,07421 claims
GSKTrelegy Ellipta, Breo Ellipta$179$29,79343 claims
Astellas Pharma US IncMyrbetriq$394$16,31424 claims
AbbVieLinzess, Synthroid$352$12,81864 claims
Lilly USA, LLCMounjaro$729$12,08513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 geriatric medicine providers in Maryland.

Other geriatric medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →